Bevacizumab (Avastin) as a surgical adjunct in diabetic vitrectomy for fibrovascular disease.
Gandhi
J S
JS
Tan
L T
LT
Pearce
I
I
Charles
S J
SJ
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D012167:Retinal Perforations / Q000139:chemically induced*; D014821:Vitrectomy
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab